TNF and rheumatoid arthritis: Higher risk for demyelinating events based on current literature includes patients on anti-TNF agents (most reported include etanercept, infliximab, and adalimumab) and patients who have a history of RA/JIA or IBD, although this is still somewhat controversial [23, 26].